Cautious optimism on factor XI inhibitor in stroke ESCCongress MedTwitter
The new factor XI inhibitor antithrombotic, milvexian , has shown promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or transient ischemic attack , when given in addition to dual antiplatelet therapy.
“Based on the observed efficacy signal for ischemic stroke, the bleeding profile, and the overall safety and tolerability, milvexian will be further studied in a phase 3 trial in a similar stroke population,” concluded lead investigator, Mukul Sharma, MD, associate professor of medicine at McMaster University, Hamilton, Ont.
of patients undergoing knee replacement in which the drug showed similar or increased efficacy in reducing thromboembolism, compared with enoxaparin, 40 mg, without an increase in major bleeding. However, milvexian was associated with a numerically lower risk for clinical ischemic stroke at all doses except 200 mg twice daily, with doses from 25 to 100 mg twice daily showing an approximately 30% relative risk reduction versus placebo .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Guidelines on GLP1RAs and Glucose MonitorsIrl B. Hirsch, MD, reviews new guidelines for glucose monitors and inhibitors.
Read more »
Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVERResults from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.
Read more »
Posthaste: Variable-rate mortgages growing in popularity despite Bank of Canada rate hikesICYMI: Variable-rate mortgages growing in popularity despite Bank of Canada rate hikes — via financialpost mortgages mortgagerates Variablerate
Read more »
Plug-in hybrids can drive us to our fully electric futurePlug-ins make sense for consumers and automakers alike
Read more »
Breakingviews - Gloves come off in India’s digital content warsThe gloves are coming off in India’s content wars, and the traditionally cautious Disney is proving a more ruthless fighter than many had expected.
Read more »
Nearing 91, artist James Hubbell has no time to waste. He's got 2 exhibits and a new tour season opening this monthThe world-famous designer and sculptor said he continues to find new inspiration and optimism, in spite of health challenges and move away from his longtime home
Read more »